Table 3.
Baseline characteristics of the inverse probability of treatment weight-matched population.
| Group B | Group C | p | SD | |
|---|---|---|---|---|
| Age | 64.31 ± 11.92 | 63.03 ± 12.52 | 0.231 | 0.104 |
| Sex (Male) | 496 (71.67) | 440 (72.95) | 0.748 | 0.029 |
| BMI, kg/m2 | 24.43 ± 3.51 | 24.40 ± 3.27 | 0.893 | 0.011 |
| Hypertension | 432 (62.39) | 346 (57.34) | 0.235 | 0.102 |
| Dyslipidemia | 170 (24.51) | 140 (23.18) | 0.722 | 0.032 |
| STEMI | 321 (46.48) | 273 (45.32) | 0.790 | 0.023 |
| Previous CVD | 105 (15.15) | 107 (17.68) | 0.426 | 0.066 |
| Beta-blocker | 512 (74.04) | 419 (69.46) | 0.247 | 0.099 |
| RAS inhibitors | 547 (79.06) | 495 (82.12) | 0.383 | 0.080 |
| statin | 613 (88.67) | 544 (90.17) | 0.548 | 0.050 |
| P2Y12 inhibitors | 667 (96.49) | 582 (96.52) | 0.985 | 0.002 |
| Aspirin | 690 (99.82) | 595 (98.66) | ||
| CCB | 104 (14.97) | 64 (10.62) | 0.160 | 0.141 |
| OHA | 517 (74.75) | 469 (77.81) | 0.400 | 0.073 |
| Insulin | 119 (17.18) | 153 (25.36) | 0.014 | 0.188 |
| Treatment | 0.899 | |||
| - None | 43 (6.20) | 35 (5.76) | 0.019 | |
| - Thrombolysis | 27 (3.89) | 26 (4.38) | 0.024 | |
| - PCI | 541 (78.25) | 483 (80.16) | 0.048 | |
| - CABG | 81 (11.65) | 59 (9.70) | 0.066 | |
| Creatinine, mg/dl | 1.30 ± 1.46 | 1.21 ± 1.03 | 0.399 | 0.072 |
| LVEF (<40%) | 102 (14.78) | 79 (13.02) | 0.557 | 0.052 |
| New DM | 190 (27.46) | 120 (19.97) | 0.078 | 0.187 |
| GRACE | 114.67 ± 35.86 | 113.34 ± 37.35 | 0.672 | 0.036 |
BMI, body mass index; STEMI, ST-elevated myocardial infarction; CVD, cardiovascular disease; RAS, renin-angiotensin-system; CCB, calcium channel blocker; OHA, oral hypoglycemic agent; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LVEF, left ventricle ejection fraction.